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Abstract
Olanzapine is an efficacious antipsychotic drug often used in the 
treatment for schizophrenia or bipolar disorder, however, some-
times induces metabolic disorders. We will introduce a patient with 
bipolar disorder, who has been treated by olanzapine and showed 
severe hypertriglyceridemia. As a result of measurements of pa-
rameters associated with lipid metabolism, very-low density lipo-
protein was the most important lipoprotein for olanzapin-induced 
hypertriglyceridemia. The cessation of olanzapine significantly de-
creased high-sensitivity C-reactive protein and increased adiponec-
tin, proposing that inflammation and reduced adiponectin level may 
be associated with olanzapin-induced hypertriglyceridemia.
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Introduction
Olanzapine is an efficacious antipsychotic drug often used in 
the treatment for schizophrenia or bipolar disorder, however, 
sometimes induces metabolic disorders such as obesity and 
hypertriglyceridemia [1, 2]. We will introduce a patient with 
bipolar disorder, who has been treated by olanzapine and 
showed severe hypertriglyceridemia. Here, we will show the 
changes in levels of triglyceride (TG), TG-rich lipoproteins, 
lipoprotein lipase (LPL), adiponectin, and high-sensitivity 
C-reactive protein (hs-CRP) at 1 and 2 months after the ces-
sation of olanzapine, which may advance the understanding 
of the underlying mechanisms for olanzapine-induced hy-
pertriglyceridemia.
Case Report
A 40-year-old man was referred to our department due to 
severe hypertriglyceridemia (TG: 1,598 mg/dl) in August 
2010. His body weight was 67 kg and height 170 cm (BMI:   
23.2 kg/m2). At the age of 23 he has been diagnosed as bi-
polar disorder, and the treatment using olanzapine started in 
March 2008. He has been treated by using levomepromazine 
(10 mg/day), lithium carbonate (800 mg/day), flunitrazepam 
(2 mg/day) and olanzapine (10 mg/day). After the cessation 
of olanzapine, he was treated by levomepromazine (10 mg/
day), lithium carbonate (800 mg/day), flunitrazepam (2 mg/
day) and quetiapine fumarate (50 mg/day). Cessation of tak-
ing olanzapine did not change his body weight, however, 
promptly decreased serum TG level (Fig. 1). To understand 
which TG-rich lipoprotein is important for olanzapine-in-
duced hypertriglyceridemia, we measured each lipoprotein 
fraction by the newly developed anion-exchange high-per-
formance liquid chromatography [3]. Serum very low-den-
sity lipoprotein cholesterol (VLDL-C) level was remarkably 
high during the olanzapine use, and was also promptly de-
creased after the cessation of olanzapine, and the decrease 
of VLDL-C almost paralleled the decrease of TG (Fig. 1). 
Serum  levels  of  other TG-rich  lipoproteins,  intermediate-
density lipoprotein (IDL)-C and chylomicron (CM)-C, de-
creased at one month after the cessation, however, again 
increased slightly at two months after the cessation (Fig. 1). 
Serum LPL levels increased at one month after the cessation, 
however, again decreased slightly at two months after the 
cessation (Fig. 2). Serum adiponectin level was constantly 
increased, and hs-CRP level was constantly and significantly 
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Figure 1. Changes in triglyceride (TG), very low-density lipoprotein-cholesterol (VLDL-C), intermediate-density lipoprotein-
cholesterol (IDL-C) and chylomicron-cholesterol (CM-C) at 1 month (m.) and 2 months (m.) after the cessation of olanzapine.
Figure 2. Changes in lipoprotein lipase (LPL), adiponectin and high-sensitivity C-reactive protein (hs-CRP) at 1 month (m.) and 
2 months (m.) after the cessation of  olanzapine.
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decreased after the cessation of olanzapine (Fig. 2).
Discussion
  
Present study suggested that VLDL is the most important 
TG-rich  lipoprotein  for  olanzapine-induced  hypertriglyc-
eridemia. The association of defective LPL activity to an 
increase in VLDL may be limited, which is supported by 
the small increase of LPL and the small decrease of IDL-C 
and CM-C after the cessation of olanzapine. The cessation 
of olanzapine leads to a significant decrease in hs-CRP and 
increase in adiponectin, proposing that the main underlying 
mechanism for olanzapine-mediated increase in VLDL may 
be olanzapine-induced inflammation and reduced adiponec-
tin.  Briefly,  olanzapine  may  induce  inflammation  and  re-
duce adiponectin, leading to activation of hormone-sensitive 
lipase which hydrolyzes TG to free fatty acids (FFA) [4]. 
Increased circulating FFA may enter the liver, resulting in 
hepatic overproduction of VLDL. 
In conclusion, our study demonstrated that VLDL is the 
most  important  TG-rich  lipoprotein  for  olanzapine-induced 
hypertriglyceridemia. The cessation of olanzapine leads to a 
significant decrease in hs-CRP and increase in adiponectin, pro-
posing that inflammation and reduced adiponectin level may be 
associated with olanzapine-induced hypertriglyceridemia.
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